Brighter Participated in the 14[th] International Conference on Advanced Technologies and Treatments for Diabetes
Brighter AB (Publ), today announced that the company's participation in the International Conference on Advanced Technologies and Treatments of Diabetes (ATTD) 2021, which was held on June 2 - 5, 2021 as a virtual event, was successful. ATTD is a scientific conference, established in 2008, that brings together renowned international experts, clinicians and caretakers, to discuss major advances in diabetes treatments, technological innovations and present the latest developments in insulin portfolio, delivery systems, pumps, glucose sensors, closed-loop systems and more.
“The uncertainties caused by the pandemic has raised many questions on how to add value when participating in a big event. Brighter early set a plan to ensure that the company could still provide content and insights to all visitors in our digital booth at this year’s ATTD virtual conference. We were pleased to take an active role together with some of the leading companies in diabetes management across the world. Interaction with the diabetes scientific community and sharing of latest insights, but also challenges within the treatment of diabetes, were very beneficial for us. It was a privilege to have distinguished speakers at Brighter’s booth sharing their expertise related to longstanding unmet needs in diabetes management, but also digital tools that could potentially support the health care sector to overcome these challenges, says Christer Trägårdh, acting CEO at Brighter AB.
One of the speakers at Brighters booth, Professor Tadej Battelino, a member of editorial boards of several diabetes journals, including Diabetes Care, Pediatric Diabetes and the Journal of Pediatric Endocrinology and Metabolism, and also co-organizer of 14 annual meetings of the ATTD conference – shared his overview on “Connected care” benefits in management of diabetes. The second speaker Dr. Adrian Heald, a Consultant Endocrinologist at Salford Royal Hospital, Senior Research Fellow at Manchester University, and Visiting Tutor at St. Peters College, Oxford, UK, has presented challenges with clinical inertia and therapy nonadherence with potential for digital tools to address these challenges and support scientific community and health care.
‘’Our activities related to participation in international scientific conferences, interaction with world recognized diabetologists and major players in diabetes healthcare are important steps for the company moving forward. Especially as a company providing solutions that might address some of the unmet needs in diabetes management and be beneficial for millions of people living with diabetes across the world.” commented Dragan Zdravkovic, Head of Medical Affairs at Brighter AB.
For further information, please contact:
Investor Relations
IR@brighter.se
Certified Adviser
Brighter’s Certified Adviser is Eminova Fondkommission AB, +46 (0)8 – 684 211 10, adviser@eminova.se, www.eminova.se.
About Brighter AB (publ)
Brighter is a health-tech company from Sweden with a vision of a world where managing chronic diseases is no longer a struggle. We believe a data-centric approach is key to provide smarter care for chronic conditions. Our daily-care solutions are designed with a vision to facilitate the flow of real-life treatment data between chronic-disease patients, their loved ones and their care providers – aiming to improve quality of life, easing the burden on healthcare systems, and opening new opportunities for data-driven research. Brighter is certified under ISO 13485. In 2019 the company won the Swecare Rising Stars Award. The Company's shares are listed on Nasdaq First North Growth Market/BRIG.